From StructContinue beyond “Personalis Has One Counterparty in Three Different Jobs”Back to the brief ↗Feed / NTRA

Natera, Inc.

NTRA

Healthcare · 336.70 +2.7% today

You’ve read what changed. Here’s whether the market is confirming it.

Isolated · not yet confirmedMarket checked 25 Aug, 15:55 GMT-4

Jodie situation report

Natera, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 26 directly disclosed connections are confirming.

Company+2.7% todayVolume comparison unavailable
Market group0 of 1 activeMolecular Diagnostics · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • Reported YoY increase in cost of product revenues of ~$60.6M (32.8%), with component rises in inventory, labor, third-party fees and depreciation.

Invalidation: The isolated read changes if NTRA's group or a disclosed connection begins moving with it.

Watch this read

Who this business touches

The relationships behind NTRA

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

ILMNIllumina, Inc.supplierFeb 27, 2026 ▾

“For example, our molecular diagnostics tests are currently only validated to perform on Illumina’s sequencing platform; in addition, Illumina is currently the sole supplier of our sequencers and related reagents for Panorama, Horizon, Signatera and Prospera,…”

ILMNIllumina, Inc.partnerFeb 27, 2026 ▾

“If we seek to achieve marketing authorization for Panorama, to the extent that Panorama incorporates Illumina’s sequencer or sequencing reagents, we may require Illumina’s cooperation in the regulatory process.”

Depended on by

PSNLPersonalis, Inc.customerMay 7, 2026 ▾

“First Quarter 2026 Highlights Total revenue of $15.5 million decreased 25%, or $5.1 million, during the first quarter of 2026 compared to the first quarter of 2025, due to (i) lower revenue from pharma testing services and other customers; (ii) an expected re…”

Filing peers

MYGNBLLNGH

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 29 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

NTRA is currently a Leader in the organic co-movement group Molecular Diagnostics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for NTRA; it is not active in the latest market snapshot.